ClinicalTrials.gg
TerminatedNCT02045095Updated Mar 14, 2019Results posted

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

A Phase 1 interventional study of MLN7243 in Advanced Malignant Solid Tumors, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose [MTD], inform the recommended phase 2 dose [RP2D], and identify the dose-limiting toxicities [DLTs]) of MLN7243.

Read the detailed description

This is a single arm Phase I study with multiple dosing cohorts as noted below:

  • Schedule A: MLN7243 1 mg
  • Schedule A: MLN7243 2 mg
  • Schedule A: MLN7243 4 mg
  • Schedule A: MLN7243 8 mg
  • Schedule A: MLN7243 12 mg
  • Schedule A: MLN7243 18 mg
  • Schedule A: MLN7243 Homozygous Mutant 4 mg
02

Conditions studied

  • Advanced Malignant Solid Tumors

Keywords

  • Drug therapy
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

  1. Male or female participants 18 years or older.
  2. Participants must have a confirmed diagnosis of an advanced, malignant solid tumor and must have failed or exhausted standard therapies or for which no standard therapy is available.
  3. (ECOG) performance status of 0 or 1.
  4. Participants with adequate hematologic and organ function.
  5. All participants must have radiographically detectable tumors with as defined by (version 1.1).
  6. Participants undergoing a procedure must have accessible lesions which are safe to biopsy.
  7. Recovered (that is, less than or equal to (\<=) Grade 1 toxicity) from the reversible effects of prior antineoplastic therapy, except alopecia.
  8. Female participants who are for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of , at the same time, from the time of signing the form through 4 months after the last dose of study drug, or agree to practice true abstinence.

    Male participants who agree to practice effective barrier contraception during the entire study treatment period through 4 months after the last dose of study drug or agree to practice true abstinence.

  9. Suitable venous access for the study-required blood sampling including PK sampling.

Exclusion criteria

Exclusion Criteria

Participants meeting any of the following exclusion criteria are not to be enrolled in the study:

  1. Participants with pre-existing cardiac impairment.
  2. Participants homozygous for the ABCG2 (BCRP) c.421C greater than (>) 1 A polymorphism will be excluded from the study until the safety of a minimum of the first 3 dose levels has been characterized and the sponsor confirms that such participants can be enrolled at doses that are at least 3-fold lower than the most recently determined safe and tolerable dose among at least 3 dose limiting toxicities (DLT)-evaluable non-homozygous participants.
  3. Participants with known active central nervous system (CNS) lesions are excluded. Systemic antineoplastic therapy or agents within 21 days before the first dose of study drug.
  4. Radiotherapy within 14 days before the first dose of study drug is not allowed except for limited field radiotherapy for palliative bone pain.
  5. For participants where tumor are required or requested:

    • Any known coagulation abnormalities that would contraindicate the tumor biopsy procedure.
    • Ongoing therapy with any anticoagulant or antiplatelet agents (example, aspirin, clopidogrel [Plavix®], heparin, or warfarin).
  6. Major surgery within 28 days before the first dose of MLN7243.
  7. Life-threatening illness unrelated to cancer.
  8. Any evidence of active infection or antibiotic therapy within 14 days before the first dose of MLN7243.
  9. Known (HIV) positivity or AIDS-related illness, virus, and virus.
  10. Participants whose weight is less than (\<) 40 kilogram (kg).
  11. History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe .
  12. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Schedule A: MLN7243 1 mg

    MLN7243 1 milligram (mg), infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or disease progression (PD) or discontinuation of study for another reason, or until study is stopped.

    Drug: MLN7243

  • Experimental
    Schedule A: MLN7243 2 mg

    MLN7243 2 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD, or discontinuation of study for another reason, or until study is stopped.

    Drug: MLN7243

  • Experimental
    Schedule A: MLN7243 4 mg

    MLN7243 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.

    Drug: MLN7243

  • Experimental
    Schedule A: MLN7243 8 mg

    MLN7243 8 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.

    Drug: MLN7243

  • Experimental
    Schedule A: MLN7243 12 mg

    MLN7243 12 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.

    Drug: MLN7243

  • Experimental
    Schedule A: MLN7243 18 mg

    MLN7243 18 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.

    Drug: MLN7243

  • Experimental
    Schedule A: MLN7243 Homozygous Mutant 4 mg

    MLN7243 homozygous mutant 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.

    Drug: MLN7243

Interventions

  • DrugTAK-243Studies of TAK-243TAK-243 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle. Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle. Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).

    Also known as: TAK-243

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)

  2. Number of Participants With Laboratory Related TEAEs by System Organ Class (SOC)

    Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)

  3. Number of Participants With Vital Sign Related TEAEs by Preferred Term (PT)

    Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)

  4. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

    Time frame: Cycle 1 Day 1 up to Cycle 1 Day 11

  5. Number of Participants With Clinically Significant Echocardiogram Abnormalities

    Time frame: Cycle 1 Day 2 up to 30 days after last dose of study drug (Cycle 10 Day 41)

  6. Number of Participants With TEAEs Related to Tropinin I and T

    Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)

Secondary outcomes

  1. Ceoi: Plasma Concentration at the End of Infusion for TAK-243

    Time frame: Cycle 1 Day 1 and 11: pre-infusion to end of infusion (up to 10 minutes)

  2. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-243

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

  3. AUCτ: Area Under the Plasma Concentration-time Curve Over the Dosing Interval for TAK-243

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

  4. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-243

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

  5. CL: Total Clearance After Intravenous Administration for TAK-243

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

  6. Vss: Volume of Distribution at Steady State for TAK-243

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

  7. Aet: Amount of TAK-243 Excreted Unchanged in Urine

    Time frame: Cycle 1 Day 1; Cycle 1 Day 11

  8. Fet: Percentage of TAK-243 Excreted Unchanged in Urine

    Time frame: Cycle 1 Day 1; Cycle 1 Day 11

  9. Terminal Phase Elimination Half-life (T1/2) for TAK-243

    Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

  10. Change From Baseline in Immunohistochemistry (IHC) Biomarkers in Tumor Biopsies at Cycle 1 Day 12 (C1D12) as Assessed by Histological Score (H-score)

    The pharmacodynamics IHC biomarkers included polyubiquitin marker and ubquityl (Ub)-histone H2B marker. H-score was a composite score that comprised of intensity and percentage of staining and was used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.

    Time frame: Baseline and Cycle 1 Day 12

  11. Change From Baseline in IHC Biomarkers in Tumor Biopsies at C1D12 as Assessed by Positive Index

    The pharmacodynamics IHC biomarkers included polyubiquitin marker and Ub-histone H2B marker. Positive index was calculated by taking the number of positive cells over the total number of cells.

    Time frame: Baseline and Cycle 1 Day 12

  12. Percentage of Participants With Best Overall Response

    Best overall response for participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to less than (\<) 10 millimeter (mm). Partial Response (PR): at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter; PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study (this includes baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least mm. The appearance of 1 or more new lesions is also considered progression.

    Time frame: Baseline up to end of study (approximately 7 months)

  13. Duration of Response

    Duration of any response (CR or PR) was defined as the time (in both days and months) from the date of first documented response per the investigator response assessment to the date of first progressive disease after the first documented response or, if the participant discontinues treatment, the date of last disease assessment as per RECIST version 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to \<10 mm. PR: at least 30% decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter.

    Time frame: Baseline up to end of study (approximately 7 months)

07

Results

Posted Mar 14, 2019

Participant flow

Participants took part in the study at 7 investigative sites in the United States from 31 January 2014 to 09 November 2016.

Participant flow — Overall Study
MilestoneSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Started3444581
Completed0000000
Not completed3444581
Withdrew: Other0010020
Withdrew: Progressive disease3324241
Withdrew: Withdrawal by subject0000300
Withdrew: Adverse event0110020

Outcome measures

PrimaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Reported as:
Number · participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
TEAEs3444481
SAEs1122140
PrimaryNumber of Participants With Laboratory Related TEAEs by System Organ Class (SOC)
Time frame:
Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Reported as:
Number · participants
Number of Participants With Laboratory Related TEAEs by System Organ Class (SOC)
participantsSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Metabolism and nutrition disorders1113141
Blood and lymphatic system disorders1112040
Investigations1120010
PrimaryNumber of Participants With Vital Sign Related TEAEs by Preferred Term (PT)
Time frame:
Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Reported as:
Number · participants
Number of Participants With Vital Sign Related TEAEs by Preferred Term (PT)
participantsSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Pyrexia0000010
Dyspnoea0010020
Dyspnoea exertional0000010
Hypertension0010010
PrimaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Time frame:
Cycle 1 Day 1 up to Cycle 1 Day 11
Reported as:
Number · participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
participantsSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities0000000
PrimaryNumber of Participants With Clinically Significant Echocardiogram Abnormalities
Time frame:
Cycle 1 Day 2 up to 30 days after last dose of study drug (Cycle 10 Day 41)
Reported as:
Number · participants
Number of Participants With Clinically Significant Echocardiogram Abnormalities
participantsSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Number of Participants With Clinically Significant Echocardiogram Abnormalities0000000
PrimaryNumber of Participants With TEAEs Related to Tropinin I and T
Time frame:
Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Reported as:
Number · participants
Number of Participants With TEAEs Related to Tropinin I and T
participantsSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Number of Participants With TEAEs Related to Tropinin I and T0010000
SecondaryCeoi: Plasma Concentration at the End of Infusion for TAK-243
Time frame:
Cycle 1 Day 1 and 11: pre-infusion to end of infusion (up to 10 minutes)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Ceoi: Plasma Concentration at the End of Infusion for TAK-243
nanogram per milliliter (ng/mL)Schedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Cycle 1 Day 178.658 ± 48.2212100.758 ± 24.0669473.075 ± 132.7667921.804 ± 258.61091276.684 ± 804.44761775.470 ± 463.8601391.000 ± NA
Cycle 1 Day 1168.073 ± 35.2718129.681 ± 52.4680273.807 ± 179.42412299.438 ± 9027.74201271.199 ± 628.45552316.282 ± 7744.9842265.000 ± NA
SecondaryAUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-243
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · nanogram hours per milliliter (ng*hr/mL)
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-243
nanogram hours per milliliter (ng*hr/mL)Schedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Cycle 1 Day 132.853 ± 17.389452.845 ± 5.6656312.714 ± 193.3829368.071 ± 8.2218867.427 ± 374.1800922.068 ± 192.2359—
Cycle 1 Day 1130.181 ± 12.888450.337 ± 8.9494178.142 ± NA———228.053 ± NA
SecondaryAUCτ: Area Under the Plasma Concentration-time Curve Over the Dosing Interval for TAK-243
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · ng*hr/mL
AUCτ: Area Under the Plasma Concentration-time Curve Over the Dosing Interval for TAK-243
ng*hr/mLSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Cycle 1 Day 1——535.581 ± NA377.812 ± NA1132.160 ± NA922.059 ± 192.1773—
Cycle 1 Day 11———506.693 ± NA663.176 ± 261.1957771.491 ± 181.7875—
SecondaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-243
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · ng*hr/mL
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-243
ng*hr/mLSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Cycle 1 Day 1——203.043 ± 10.0600375.541 ± 11.2872579.122 ± 201.1755768.728 ± 174.9927—
Cycle 1 Day 11——179.726 ± NA509.785 ± NA752.152 ± NA864.533 ± 175.9351—
SecondaryCL: Total Clearance After Intravenous Administration for TAK-243
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · liter per hour (L/hr)
CL: Total Clearance After Intravenous Administration for TAK-243
liter per hour (L/hr)Schedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Cycle 1 Day 1——19.724 ± 0.977321.312 ± 0.640622.749 ± 8.896724.379 ± 5.6587—
Cycle 1 Day 11——22.162 ± NA15.789 ± NA16.194 ± NA21.558 ± 4.8376—
SecondaryVss: Volume of Distribution at Steady State for TAK-243
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · liter
Vss: Volume of Distribution at Steady State for TAK-243
literSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Cycle 1 Day 1——29.806 ± 0.949433.957 ± 5.827337.596 ± 20.752063.744 ± 39.5945—
Cycle 1 Day 11——34.120 ± NA39.618 ± NA56.573 ± NA51.806 ± 18.8787—
SecondaryAet: Amount of TAK-243 Excreted Unchanged in Urine
Time frame:
Cycle 1 Day 1; Cycle 1 Day 11

No measurements were reported for this outcome.

SecondaryFet: Percentage of TAK-243 Excreted Unchanged in Urine
Time frame:
Cycle 1 Day 1; Cycle 1 Day 11

No measurements were reported for this outcome.

SecondaryTerminal Phase Elimination Half-life (T1/2) for TAK-243
Time frame:
Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Reported as:
Mean · hour
Terminal Phase Elimination Half-life (T1/2) for TAK-243
hourSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Cycle 1 Day 1——7.001 ± 1.43729.377 ± 4.64425.765 ± 0.86078.296 ± 4.3573—
Cycle 1 Day 11——5.572 ± NA15.212 ± NA27.446 ± NA9.873 ± 6.3030—
SecondaryChange From Baseline in Immunohistochemistry (IHC) Biomarkers in Tumor Biopsies at Cycle 1 Day 12 (C1D12) as Assessed by Histological Score (H-score)

The pharmacodynamics IHC biomarkers included polyubiquitin marker and ubquityl (Ub)-histone H2B marker. H-score was a composite score that comprised of intensity and percentage of staining and was used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.

Time frame:
Baseline and Cycle 1 Day 12
Reported as:
Mean · score on a scale
Change From Baseline in Immunohistochemistry (IHC) Biomarkers in Tumor Biopsies at Cycle 1 Day 12 (C1D12) as Assessed by Histological Score (H-score)
score on a scaleSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Baseline: Polyubiquitin H-score286.00 ± NA297.80 ± NA282.00 ± NA————
Change at C1D12: Polyubiquitin H-score-3.60 ± NA-2.00 ± NA4.20 ± NA————
Baseline: Ub-histone H2B H-score269.750 ± NA291.000 ± NA290.750 ± NA————
Change at C1D12: Ub-histone H2B H-score13.250 ± NA3.250 ± NA2.000 ± NA————
SecondaryChange From Baseline in IHC Biomarkers in Tumor Biopsies at C1D12 as Assessed by Positive Index

The pharmacodynamics IHC biomarkers included polyubiquitin marker and Ub-histone H2B marker. Positive index was calculated by taking the number of positive cells over the total number of cells.

Time frame:
Baseline and Cycle 1 Day 12
Reported as:
Mean · percentage of cell
Change From Baseline in IHC Biomarkers in Tumor Biopsies at C1D12 as Assessed by Positive Index
percentage of cellSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Baseline: Polyubiquitin Positive Index0.99 ± NA1.00 ± NA0.99 ± NA————
Change at C1D12: Polyubiquitin Positive Index-0.01 ± NA0.00 ± NA0.00 ± NA————
Baseline: Ub-histone H2B Positive Index0.953 ± NA0.995 ± NA0.990 ± NA————
Change at C1D12: Ub-histone H2B Positive Index0.018 ± NA0.003 ± NA-0.003 ± NA————
SecondaryPercentage of Participants With Best Overall Response

Best overall response for participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to less than (\<) 10 millimeter (mm). Partial Response (PR): at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter; PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study (this includes baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least mm. The appearance of 1 or more new lesions is also considered progression.

Time frame:
Baseline up to end of study (approximately 7 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response
percentage of participantsSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
CR0000000
PR33000000
SD6775100050600
PD02501005040100
SecondaryDuration of Response

Duration of any response (CR or PR) was defined as the time (in both days and months) from the date of first documented response per the investigator response assessment to the date of first progressive disease after the first documented response or, if the participant discontinues treatment, the date of last disease assessment as per RECIST version 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to \<10 mm. PR: at least 30% decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter.

Time frame:
Baseline up to end of study (approximately 7 months)
Reported as:
Median · months
Duration of Response
monthsSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Duration of Response6.24 (6.24 to 6.24)——————

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days (Cycle 10 Day 41) after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Schedule A: TAK-243 1 mg—1/3 (33.3%)3/3 (100%)
Schedule A: TAK-243 2 mg—1/4 (25%)4/4 (100%)
Schedule A: TAK-243 4 mg—2/4 (50%)4/4 (100%)
Schedule A: TAK-243 8 mg—2/4 (50%)4/4 (100%)
Schedule A: TAK-243 12 mg—1/5 (20%)3/5 (60%)
Schedule A: TAK-243 18 mg—4/8 (50%)8/8 (100%)
Schedule A: TAK-243 Homozygous Mutant 4 mg—0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
Escherichia bacteraemiaInfections and infestations1/30/40/40/40/50/80/1
PneumoniaInfections and infestations0/30/40/41/41/50/80/1
Abdominal painGastrointestinal disorders0/31/40/40/40/50/80/1
Breathing abnormalitiesRespiratory, thoracic and mediastinal disorders0/30/40/40/40/52/80/1
DyspnoeaRespiratory, thoracic and mediastinal disorders0/30/40/40/40/52/80/1
Respiratory failureRespiratory, thoracic and mediastinal disorders0/30/40/41/40/50/80/1
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/40/41/40/50/80/1
AnaemiaBlood and lymphatic system disorders0/30/40/41/40/50/80/1
Acute myocardial infarctionCardiac disorders0/30/41/40/40/50/80/1
Infusion related reactionInjury, poisoning and procedural complications0/30/41/40/40/50/80/1
Most frequent other events
Showing 10 of 91
Most frequent other events
EventSchedule A: TAK-243 1 mgSchedule A: TAK-243 2 mgSchedule A: TAK-243 4 mgSchedule A: TAK-243 8 mgSchedule A: TAK-243 12 mgSchedule A: TAK-243 18 mgSchedule A: TAK-243 Homozygous Mutant 4 mg
HyponatraemiaMetabolism and nutrition disorders0/30/40/41/40/50/81/1
Neuropathy peripheralNervous system disorders0/30/40/40/40/50/81/1
NauseaGastrointestinal disorders1/33/41/40/40/53/80/1
AnaemiaBlood and lymphatic system disorders0/31/41/41/40/54/80/1
VomitingGastrointestinal disorders0/32/40/40/41/54/80/1
Decreased appetiteMetabolism and nutrition disorders0/31/40/42/40/51/80/1
ArthralgiaMusculoskeletal and connective tissue disorders0/32/42/41/40/52/80/1
Back painMusculoskeletal and connective tissue disorders0/32/40/41/40/50/80/1
FatigueGeneral disorders1/30/41/41/42/51/80/1
LeukopeniaBlood and lymphatic system disorders1/30/40/40/40/51/80/1

Baseline characteristics

The safety population included all participants who received at least 1 dose of TAK-243.

Age, Continuous
Age, Continuous(years)Schedule A: TAK-243 Total
Mean56.8 ± 9.27
Sex: Female, Male
Sex: Female, Male(Participants)Schedule A: TAK-243 Total
Female12
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Schedule A: TAK-243 Total
Hispanic or Latino2
Not Hispanic or Latino22
Unknown or Not Reported5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Schedule A: TAK-243 Total
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White22
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(Participants)Schedule A: TAK-243 Total
United States29
Height
Height(centimeter (cm))Schedule A: TAK-243 Total
Mean170.88 ± 12.101
Weight
Weight(kilogram (kg))Schedule A: TAK-243 Total
Mean79.69 ± 16.829
Body Surface Area
Body Surface Area(square meter (m^2))Schedule A: TAK-243 Total
Mean1.936 ± 0.2364
08

Study locations

7 sites
  • Boston, Massachusetts, United States
  • Saint Louis, Missouri, United States
  • Cleveland, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • San Antonio, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Nov 2016, 33 months.

Results were first posted in Mar 2019, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2013
First posted
Jan 24, 2014
StartActual
Jan 31, 2014
Primary completionActual
Nov 9, 2016
CompletionActual
Nov 9, 2016
Results first posted
Mar 14, 2019
Last update
Mar 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02045095
Responsible party
Sponsor
First posted
Jan 24, 2014
Start date
Jan 31, 2014
Primary completion
Nov 9, 2016
Completion
Nov 9, 2016
Results posted
Mar 14, 2019
Last update
Mar 14, 2019

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-243

Start the discussion